DGU Congress 2024

Meet BIOTYPE in Leipzig at DGU 2024!

Exciting advancements have been made in targeted therapies for urothelial carcinoma. With these therapies becoming available, it's essential to improve biomarker testing, especially in bladder cancer.

Testing for somatic mutations and FGFR gene fusions can help identify patients eligible for new targeted treatments.

Get in touch with Vanessa Grunwald, Product Manager, Rebekka Weißbach, Senior Scientist, and Sabine Kiessling-Parr, BD Manager at the 76. Annual Congress of the DGU, in Leipzig on September 25th - 27thand discover how BIOTYPE’s diagnostics and services can meet the needs you may have for a rapid, robust and comprehensive testing on actionable FGFR alterations to stratify patients in their treatment journey efficiently.

To address any questions you may have, we would be delighted to arrange a meeting with you or your colleagues in Leipzig during the conference.

Schedule your meeting with Vanessa Grunwald, Rebekka Weißbach, and Sabine Kiessling-Parr via LinkedIn!